IVERIC bio (formerly known as Ophthotech) is a biopharmaceutical company engaged in the discovery and development of treatment options for retinal diseases. It offers Zimura, an inhibitor of complement factor C5 for the treatment of geographic atrophy, a late-stage form of dry age-related macular degeneration, characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula, and autosomal recessive Stargardt disease, which is an orphan inherited retinal disease.